327 related articles for article (PubMed ID: 21175227)
21. [When should anti-TNF-alpha treatment in Crohn disease be terminated?].
Moum B
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):474. PubMed ID: 20224609
[No Abstract] [Full Text] [Related]
22. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
23. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
Michetti P
Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883
[No Abstract] [Full Text] [Related]
24. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
25. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
26. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
27. Guidelines for the management of inflammatory bowel disease in adults.
Carter MJ; Lobo AJ; Travis SP;
Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
[No Abstract] [Full Text] [Related]
28. Occurrence of plantar pustular psoriasis during treatment with infliximab.
English PL; Vender R
J Cutan Med Surg; 2009; 13(1):40-2. PubMed ID: 19298770
[TBL] [Abstract][Full Text] [Related]
29. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
30. [Anti-TNF therapy and Crohn's disease].
Peyrin-Biroulet L
Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
[No Abstract] [Full Text] [Related]
31. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
Wittig BM; Zeitz M
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
[No Abstract] [Full Text] [Related]
32. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
33. Infliximab use in children and adolescents with inflammatory bowel disease.
de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
[TBL] [Abstract][Full Text] [Related]
34. [Drug therapy of inflammatory bowel diseases].
Silvennoinen J; Niemelä S
Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
[No Abstract] [Full Text] [Related]
35. Medical therapy of IBD in 2009.
Harris A; Feller ER; Shah SA
Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
[No Abstract] [Full Text] [Related]
36. Anti-TNFalpha therapy in a rare case of Crohn's disease: still a panacea.
Verburg R; Zelissen P; Rothova A; Siersema PD; Oldenburg B
Inflamm Bowel Dis; 2008 Oct; 14(10):1457-60. PubMed ID: 18383178
[No Abstract] [Full Text] [Related]
37. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
Bujanover Y; Weiss B
Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
[No Abstract] [Full Text] [Related]
39. Update on anti-tumor necrosis factor agents in Crohn disease.
Singh S; Pardi DS
Gastroenterol Clin North Am; 2014 Sep; 43(3):457-78. PubMed ID: 25110253
[TBL] [Abstract][Full Text] [Related]
40. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
